MELANOMA INSTITUTE AUSTRALIA
Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
The Multicentre Selective Lymphadenectomy Trial - 3
- Conditions
- Cutaneous Melanoma, Stage III
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 1500
- Registration Number
- NCT07049276
- Locations
- 🇺🇸
Cedars-Sinai Medical Centre, Los Angeles, California, United States
🇦🇺Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
A Phase II, Randomised Clinical Trial of Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
- Conditions
- Cutaneous MelanomaMucosal Melanoma
- Interventions
- Drug: Ipilimumab 3mg/kg and nivolumab 1mg/kgDrug: Nivolumab 480mg and relatlimab 160mg and ipilimumab 1mg/kgDrug: Nivolumab 480mg and relatlimab 160mg
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 297
- Registration Number
- NCT06999980
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
- Conditions
- Melanoma Metastatic
- Interventions
- Drug: Immunotherapy alone
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 129
- Registration Number
- NCT06767306
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Personalised Immunotherapy Platform
- Conditions
- Basal Cell CarcinomaSolid TumorMelanomaCutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 1000
- Registration Number
- NCT06536257
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
🇦🇺Melanoma Institute Australia, Sydney, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT06288191
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
- Prev
- 1
- 2
- 3
- 4
- Next
News
Phase 3 Trial Shows Promise for Adjuvant BRAF/MEK Inhibitor Combination in High-Risk Melanoma
The phase 3 EORTC-2139-MG/Columbus-AD trial demonstrated that adjuvant encorafenib plus binimetinib improved 12-month recurrence-free survival to 86% versus 70% with placebo in patients with stage IIB/C BRAF V600-mutant melanoma.
Strand Therapeutics Reports Promising Phase 1 Data for Novel mRNA Cancer Therapy STX-001
Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors.
Novel Triple Immunotherapy Approach Shows Promise in Glioblastoma Treatment
A groundbreaking experimental treatment combining three checkpoint inhibitor immunotherapies before surgery has shown promising results in glioblastoma, with one patient remaining cancer-free for over 18 months.
Combination Immunotherapy Achieves 51% Seven-Year Survival Rate in Advanced Melanoma Brain Metastases
Australian clinical trial demonstrates unprecedented 51% survival rate at seven years for melanoma patients with brain metastases using combination immunotherapy with nivolumab and ipilimumab.
Neoadjuvant Immunotherapy Solidifies as Standard of Care in Stage III Melanoma
Updated data from the NADINA trial demonstrates that neoadjuvant ipilimumab plus nivolumab significantly improves event-free and distant metastasis-free survival compared to adjuvant nivolumab in resectable stage III melanoma.
Pioneering Immunotherapy Approach Keeps Brain Cancer at Bay for Australian Doctor Who Helped Develop It
Professor Richard Scolyer, diagnosed with terminal stage 4 glioblastoma in 2023, remains cancer-free one year after receiving a first-of-its-kind immunotherapy treatment he helped develop.